GRIK5

Glutamate receptor ionotropic, kainate 5 · Q16478 · GRIK5 on Sugi Atlas →

19,274 patent compounds predicted against GRIK5, 12,672 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL401659	1.00	9/20
Quisqualate (SCHEMBL136819)	0.45	9/20
(S)-Willardiine (SCHEMBL401191)	0.56	6/20
(S)-Willardiine (SCHEMBL438494)	0.56	6/20
Fanapanel (SCHEMBL353357)	0.48	5/20
Mimosine (SCHEMBL41924)	0.42	5/20
L-Mimosine (SCHEMBL41925)	0.42	5/20
Aspartic Acid (SCHEMBL135731)	0.57	4/20
Aspartic Acid (SCHEMBL464907)	0.50	4/20
Aspartic Acid (SCHEMBL464908)	0.50	4/20
Aspartic Acid (SCHEMBL305804)	0.48	4/20
Aspartic Acid (SCHEMBL305805)	0.48	4/20
SCHEMBL497587	0.47	4/20
Asparagine (SCHEMBL15460)	0.46	4/20
Asparagine (SCHEMBL38379)	0.46	4/20
Asparagine (SCHEMBL150535)	0.46	4/20
Asparagine (SCHEMBL288093)	0.46	4/20
Asparagine (SCHEMBL288094)	0.46	4/20
Asparagine (SCHEMBL289546)	0.46	4/20
Asparagine (SCHEMBL50254)	0.45	4/20

Clinical trials — most relevant to GRIK5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial	PHASE2/PHASE3	NOT_YET_RECRUITING
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease	PHASE3	COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD	PHASE2	RECRUITING
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue	PHASE1/PHASE2	COMPLETED
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203	PHASE1	COMPLETED
Brain Imaging, Genetics and Treatment for Major Depression	PHASE1	WITHDRAWN
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial	PHASE1	COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response	PHASE1	RECRUITING
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
Diclofenac Dose Response Study	PHASE1	RECRUITING
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression	PHASE1	RECRUITING
Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain	PHASE1	COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Acamprosate: Genes Associated With Response	nan	COMPLETED
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients	nan	COMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
(GluEsk) Glutamate and Esketamine	nan	COMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
Mechanisms of Human Plasticity in the Human System	nan	COMPLETED
Functional Study of Inhibitory Neurotransmission in the Human Epileptic Brain.	nan	RECRUITING
Comparison of the Effects of Dexmedetomidine and Lidocaine on Blood Pressure and Heart Rate Response	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GRIK5 binder may also engage these)

Protein	Name	Similarity
Q61626	—	1.000	Q61626 →
Q63273	—	1.000	Q63273 →
Q01812	—	1.000	Q01812 →
Q5IS46	—	0.996	Q5IS46 →
Q8BMF5	—	0.996	Q8BMF5 →
Q38PU2	—	0.994	Q38PU2 →
P42264	—	0.993	P42264 →
B1AS29	—	0.992	B1AS29 →
GRIK4	Glutamate receptor ionotropic, kainate 4 (Glu	0.991	landscape →
Q60934	—	0.991	Q60934 →
P34299	—	0.989	P34299 →
P39087	—	0.988	P39087 →
Q38PU3	—	0.987	Q38PU3 →
P42260	—	0.987	P42260 →
Q90218	—	0.986	Q90218 →
P26591	—	0.986	P26591 →
GRIK2	Glutamate receptor ionotropic, kainate 2	0.986	landscape →
GRIK3	Glutamate receptor ionotropic, kainate 3	0.986	landscape →
A0A2R8QF68	—	0.986	A0A2R8QF68 →
Q80T41	—	0.985	Q80T41 →
Q9Z2W8	—	0.985	Q9Z2W8 →
Q91755	—	0.985	Q91755 →
G5ECB2	—	0.985	G5ECB2 →
GRIK1	Glutamate receptor ionotropic, kainate 1	0.984	landscape →
P19439	—	0.983	P19439 →
Q09630	—	0.982	Q09630 →
Q7XP59	—	0.982	Q7XP59 →
P22756	—	0.982	P22756 →
Q91756	—	0.982	Q91756 →
GRIA4	Glutamate receptor 4	0.982	landscape →